SGS increases biopharmaceutical testing capabilities in Switzerland

Published: 13-Apr-2023

The move has expanded the capacity of the laboratory for biologic structural characterisation and offers enhanced identification

SGS has relocated its Plan-les-Ouates, Switzerland-based biopharmaceutical testing laboratory in a move from the previous 750 m2 facility to a new 2,100 m2 laboratory and office space.

The move has expanded the capacity of the laboratory for biologic structural characterisation. Additionally, the laboratory offers enhanced identification and quantification for both process and product-related impurities. The lab has also successfully renewed its Swissmedic GMP audit.

As a European Center of Excellence for nitrosamines testing, the new SGS laboratory has also been equipped with two state-of-the-art LC-HRMS instruments to support clients with compliance and safety assurance.

Plan-les-Ouates laboratory services overview

Boasting over 30 years of experience, the Plan-les-Ouates laboratory is a Center of Excellence for biopharmaceutical characterization and quantification. Its team of scientists, highly experienced in method development and validation, offer a range of valuable testing services to SGS clients, including:

Biopharmaceutical structural characterisation:

  • Molecular weight determination
  • Post-translational modification identification
  • Amino acid composition
  • N- and C-terminal sequencing
  • Peptide mapping
  • Sulfhydryl group and disulfide bridge analysis
  • Conjugate site identification
  • Full protein sequencing
  • Glycosylation analysis
  • Oligonucleotide analysis

Biopharmaceutical physico-chemical properties analysis:

  • Secondary structure
  • Tertiary structure
  • Low molecular mass oligomers and aggregates (1-100 nm)
  • High molecular mass aggregates and particles
  • Thermal stability

Quantification by LC-MS:

  • Product- and process-related impurity quantification
  • Protein and peptide quantification in complex protein mixtures and matrices

The facility will see further developments in 2023 with the building of a BSL-2 laboratory. This ongoing investment will extend SGS’ status as a global leader in analytical services and help the company support the development of the cell & gene therapy field.

Relevant companies

You may also like